Colin Lindsay, BSc, MBChB, MRCP, PhD, Christie NHS Foundation Trust, Manchester, UK, discusses challenges in G12C targeting for the treatment of patients with KRAS-mutant lung cancer, commenting on the role of x-ray crystallography in drug development and the need for novel approaches for targeting other KRAS mutations, such as G12V and G12D. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.
